Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. The companys drug Ocaliva has been approved for primary biliary cholangitis. Additionally, Dan is a Scientist and inventor. Rumors. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. Biotech M&A - 2021 Deals Search for: Biotech M&A - 2021 Deals. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. Copyright Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. BioPharma Dive is tracking these deals below. It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. I have no business relationship with any company whose stock is mentioned in this article. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. There were a few, but not as many. Alexion Pharmaceuticals. This conference call is no longer online, but the. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Price as of January 17, 2023, 4:00 p.m. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. The uptake of all these products has been good. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc. Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company. Do Not Sell My Personal Information (CA Residents Only). Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. The company has already seven products on the market. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Invest better with The Motley Fool. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. After a rather bumpy start with disappointing sales numbers in 2019 and 2020, CAPLYTA net product revenues for the second quarter 2022 showed a 190% increase as compared to the same period in 2021 and a 58% increase over the first quarter 2022. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. I think those could be intriguing deals for the new year. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! 6. The Motley Fool has a disclosure policy. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Speights: Yeah. Scott has had the most success in trading/investing in smaller cap growth companies. BioSpace is covering all the key announcements all week. Cost basis and return based on previous market day close. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. I own Seagen. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Someone is "mistaken" here. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. Disclosure: I am long ATRS, SLTM, ACRX. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". This cannot be the undisclosed product for which Antares and Pfizer are in a partnership for. "Human natural killer cell" [Micrograph]. Cost basis and return based on previous market day close. I wrote this article myself, and it expresses my own opinions. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. In case of a buyout, investors often benefit of a massive premium. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. 12. No. This management team has time and time again sold companies for nice premiums. No. Here's a look at the 10 top takeover targets. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. These deals haven't come cheap, however. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Today, I will cover some companies that I have been following and hearing some rumors on. One of the catalysts that could work in its favor is deal optimism. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. While Some Have Learned From It, Others Wont. RTTNews->. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. 11. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. The quest behind the drive is to fill potential gaps in the pipeline. These symbols will be available throughout the site during your session. After a lengthy drought, could biotech M&A be on the upswing? Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. National Institutes of Allergy and Infectious Diseases. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. 9. Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. Type a symbol or company name. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Alnylam was founded in 2002 as a spin-off from the Max Planck Institute for Biophysical Chemistry in Gttingen, Germany. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. Best Penny Stocks . 7. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. Are some major acquisitions on the way in the biopharmaceutical industry this year? The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Create your Watchlist to save your favorite quotes on Nasdaq.com. *Average returns of all recommendations since inception. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). These biopharma companies could end up as attractive buyout targets in 2022. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Antares Pharma. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Medarex bought out GenPharm for $65M. BioMarin is almost every analyst's favorite takeover candidate. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. I don't know, maybe they could out-license those. Making the world smarter, happier, and richer. They could develop that in combination. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Acquisitions are back in full swing in the sector. 13. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. However, the Company has turned down Elliott's recommendation. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. Cash position at the end of the fiscal year was at $1.52 billion. Making the world smarter, happier, and richer. Please. Someone is "mistaken" here. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. I think that would potentially drive sales of Opdivo. Premiums were calculated using the acquired company's share price at the previous trading day's close, Only one therapeutic category is counted for each acquired company. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. To make the world smarter, happier, and richer. earnings call is. Later, Bristol-Myers Squibb for $2.4B. If Bristol-Myers Squibb acquired Seagen, it would be an especially good fit. Pharma giant Pfizer recently announced that it will acquire Arena. Clovis announced a $71.3 million net loss for the second quarter of 2022. An early-stage asset, codenamed BMN 307, is mired in trouble. But I think there's also a good fit on Seagen's pipeline too. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved.